Efficacy of a simethicone, activated charcoal and magnesium oxide combination (Carbosymag®) in functional dyspepsia: Results of a general practice-based randomized trial - 14/06/11
, Claude Bortolloti c, Odile Bourgeois d, Luc Denicourt e
Corresponding author. Tel.: +33 1 47 60 60 61; fax: +33 1 47 60 60 72.Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
| pagine | 6 |
| Iconografia | 2 |
| Video | 0 |
| Altro | 0 |
Summary |
Background |
A simethicone, activated charcoal and magnesium oxide combination (Carbosymag®) has been used for almost 20years in functional dyspepsia, but there is limited scientific evidence of efficacy.
Aim |
We evaluated the efficacy of Carbosymag® in 18- to 49-year-old patients with functional dyspepsia.
Methods |
A total of 276 dyspeptic patients consulting a general practitioner and meeting the Rome III criteria were included in this prospective placebo-controlled study. Variations in overall and individual dyspeptic symptoms were evaluated after 1 month of treatment.
Results |
At the end of the treatment period, overall dyspeptic symptom intensity was significantly lower in the Carbosymag® group (P=0.01). The intensity of post-prandial fullness, epigastric pain, epigastric burning and abdominal bloating was significantly reduced in the Carbosymag® group relative to the placebo group (P<0.05). The number need to treat to induce a 70-% decrease in overall dyspeptic symptoms by Carbosymag® was 7 (IC 95%: 4–32).
Conclusion |
A simethicone, activated charcoal and magnesium oxide combination (Carbosymag®) was significantly more effective than a placebo on overall symptom intensity in dyspeptic patients consulting a general practitioner.
Il testo completo di questo articolo è disponibile in PDF.Mappa
Vol 35 - N° 6-7
P. 494-499 - Giugno 2011 Ritorno al numero
Articolo precedente
- Diagnostic accuracy of cascade stomach by upper gastrointestinal endoscopy in patients with obscure symptoms: A multi-center prospective trial
- Murat Taner Gulsen, Irfan Koruk, Metin Dogan, Yavuz Beyazit
- Diagnostic challenges of nonalcoholic fatty liver disease (NAFLD) in children of normal weight
- Jason Y.K. Yap, Constance O’Connor, Diana R. Mager, Glenn Taylor, Eve A. Roberts
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?